ATAI
ATAI Life Sciences NV
$
4.130
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
4.2012
Open
4.200
VWAP
4.12
Vol
3.58M
Mkt Cap
876.15M
Low
4.040
Amount
14.76M
EV/EBITDA(TTM)
--
Total Shares
167.41M
EV
806.21M
EV/OCF(TTM)
--
P/S(TTM)
366.61
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. The Company focused on developing treatments for mental health disorders. The Company's pipeline includes psychedelic and non-psychedelic compounds targeting depression, anxiety, and other unmet needs in psychiatry.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
0.00
-100%
-0.120
-50%
0.00
-100%
-0.113
-29.17%
--
--
-0.118
-67.13%
Estimates Revision
The market is revising Upward the revenue expectations for Atai Life Sciences N.V. (ATAI) for FY2025, with the revenue forecasts being adjusted by 167.46% over the past three months. During the same period, the stock price has changed by 197.12%.
Revenue Estimates for FY2025
Revise Upward
+167.46%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+20.48%
In Past 3 Month
Stock Price
Go Up
+197.12%
In Past 3 Month
7 Analyst Rating
134.14% Upside
Wall Street analysts forecast ATAI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATAI is 9.67 USD with a low forecast of 6.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
0 Hold
0 Sell
Strong Buy
134.14% Upside
Current: 4.130
Low
6.00
Averages
9.67
High
12.00
134.14% Upside
Current: 4.130
Low
6.00
Averages
9.67
High
12.00
Oppenheimer
Oppenheimer
Outperform
maintain
$14 -> $16
2025-08-01
Reason
Oppenheimer
Oppenheimer
Price Target
$14 -> $16
2025-08-01
maintain
Outperform
Reason
Oppenheimer raised the firm's price target on Atai Life Sciences to $16 from $14 and keeps an Outperform rating on the shares as recent dynamics bode well for BPL-003. As large cap players vie for leadership in neuroscience, psychiatry is increasingly in focus while acquisitions of smaller players are an important source of innovation, Oppenheimer notes.
H.C. Wainwright
Patrick Trucchio
Buy
maintain
$10 -> $15
2025-07-30
Reason
H.C. Wainwright
Patrick Trucchio
Price Target
$10 -> $15
2025-07-30
maintain
Buy
Reason
H.C. Wainwright analyst Patrick Trucchio raised the firm's price target on Atai Life Sciences to $15 from $10 and keeps a Buy rating on the shares. The firm remains bullish on Atai despite the Phase 2b trial evaluating inidascamine in patients with cognitive impairment associated with schizophrenia missing the primary endpoint. In a follow-up call, management reiterated the company focus on the company's wholly-owned psychedelics pipeline, including BPL-003, which has continued to exceed expectations, the analyst tells investors in a research note. H.C. Wainwright cites Atai's focus on its "most promising near-term asset" for the target increase.
Oppenheimer
Outperform
initiated
$14
2025-07-29
Reason
Oppenheimer
Price Target
$14
2025-07-29
initiated
Outperform
Reason
Oppenheimer initiated coverage of Atai Life Sciences with an Outperform rating and $14 price target. The firm says Atai is the leading the psychedelic revolution within neuropsychiatry. The market opportunity is underappreciated considering 10M patients could benefit from alternative approaches, the analyst tells investors in a research note. Atai's Phase 2b data for BPL-003 solidify a "transformational approach," the analyst tells investors in a research note.
Canaccord
Buy
downgrade
$12 -> $11
2025-07-28
Reason
Canaccord
Price Target
$12 -> $11
2025-07-28
downgrade
Buy
Reason
Canaccord lowered the firm's price target on Atai Life Sciences to $11 from $12 and keeps a Buy rating on the shares. The firm noted they announced that inidascamine (formerly RL-007), a non-psychedelic, did not meet its primary endpoint in a Phase 2b trial for cognitive impairment associated with schizophrenia (CIAS), but showed some numerical improvements on cognitive and functional scores. Canaccord believes the weakness presents a solid oportunity to buy the shares on a more streamlined focus.
Canaccord
Buy
maintain
$11 -> $12
2025-07-02
Reason
Canaccord
Price Target
$11 -> $12
2025-07-02
maintain
Buy
Reason
Canaccord raised the firm's price target on Atai Life Sciences to $12 from $11 and keeps a Buy rating on the shares. The firm believes shares remain significantly undervalued following the release of solid Phase 2b data for BPL-003 (intranasal mebufotenin or 5-MeO-DMT) for treatment-resistant depression (TRD). They view the results as very encouraging as BPL-003 hit its primary and all key secondary endpoints convincingly. These results pave the way for the recently-announced ATAI-Beckley merger to close, which is on track for 2H25.
Jefferies
Andrew Tsai
maintain
$6
2025-07-01
Reason
Jefferies
Andrew Tsai
Price Target
$6
2025-07-01
maintain
Reason
Jefferies analyst Andrew Tsai sees potential for a 50%-100% stock move for shares of Atai Life Sciences following partner Beckley's "robust" Phase 2b data for BPL-003 in patients with treatment-resistant depression. Given the "rapid efficacy," followed by a "meaningful" and statistically significant reduction in depressive symptoms by Week 4 and "clear durability" to Week 8, the data "should instill confidence in a $1B+ drug," the analyst tells investors. Jefferies has a Buy rating and $6 price target on Atai shares, which are up 66c, or 30%, to $2.85 in pre-market trading.
See All Ratings
Valuation Metrics
The current forward P/E ratio for ATAI Life Sciences NV (ATAI.O) is -8.53, compared to its 5-year average forward P/E of -4.63. For a more detailed relative valuation and DCF analysis to assess ATAI Life Sciences NV 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-4.63
Current PE
-8.53
Overvalued PE
-0.54
Undervalued PE
-8.72
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-3.45
Current EV/EBITDA
-7.95
Overvalued EV/EBITDA
1.89
Undervalued EV/EBITDA
-8.79
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
25630.78
Current PS
5332.23
Overvalued PS
86202.13
Undervalued PS
-34940.57
Financials
Annual
Quarterly
FY2025Q1
1.56M
Total Revenue
FY2025Q1
YoY :
-13.14%
-19.27M
Operating Profit
FY2025Q1
YoY :
+3.07%
-26.47M
Net Income after Tax
FY2025Q1
YoY :
-11.76%
-0.15
EPS - Diluted
FY2025Q1
YoY :
+5.67%
-23.86M
Free Cash Flow
FY2025Q1
100.00
Gross Profit Margin - %
FY2025Q1
YoY :
-85.46%
-4.50K
FCF Margin - %
FY2025Q1
-1.70K
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
246.0K
USD
5
6-9
Months
0.0
USD
0
0-12
Months
16.1M
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
1
2.5M
USD
Months
6-9
1
22.8M
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 121.2% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
1
2.1M
Volume
Months
6-9
1
949.4K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
246.0K
USD
5
6-9
Months
0.0
USD
0
0-12
Months
16.1M
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
1
2.5M
USD
Months
6-9
1
22.8M
USD
Months
0-12
0
0.0
USD
Months
ATAI News & Events
Events Timeline
2025-07-25 (ET)
2025-07-25
16:06:52
Recognify provides update on Phase 2b trial of inidascamine
2025-07-01 (ET)
2025-07-01
09:56:42
Atai data supports 'best-in-class potential' of BPL-003, says H.C. Wainwright
2025-07-01
06:06:58
Atai Life Sciences, Beckley Psytech report positive Phase 2b results of BPL-003
Sign Up For More Events
Sign Up For More Events
News
8.0
08-07MarketWatchHow options trading offers clues to these 3 tech stocks’ postearnings moves
9.5
07-31MarketWatchMicrosoft and Meta are pushing the stock market into even more overbought territory
4.0
07-30BenzingaThis IonQ Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Sign Up For More News
People Also Watch
AVNW
Aviat Networks Inc
21.810
USD
+4.45%
EVI
EVI Industries Inc
23.160
USD
-0.04%
GENC
Gencor Industries Inc
14.860
USD
+1.99%
ALTG
Alta Equipment Group Inc
7.740
USD
+7.95%
ZYXI
Zynex Inc
1.450
USD
-1.36%
DMAC
DiaMedica Therapeutics Inc
4.670
USD
-3.11%
PINE
Alpine Income Property Trust Inc
14.140
USD
-0.28%
NAUT
Nautilus Biotechnology Inc
0.731
USD
-1.88%
CPSS
Consumer Portfolio Services Inc
8.020
USD
+0.50%
FAQ
What is ATAI Life Sciences NV (ATAI) stock price today?
The current price of ATAI is 4.13 USD — it has decreased -0.48 % in the last trading day.
What is ATAI Life Sciences NV (ATAI)'s business?
What is the price predicton of ATAI Stock?
What is ATAI Life Sciences NV (ATAI)'s revenue for the last quarter?
What is ATAI Life Sciences NV (ATAI)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for ATAI Life Sciences NV (ATAI)'s fundamentals?
How many employees does ATAI Life Sciences NV (ATAI). have?